Höpken Uta E, Rehm Armin
Department of Microenvironmental Regulation in Autoimmunity and Cancer, Max-Delbrück-Center for Molecular Medicine, MDC, 13125, Berlin, Germany.
Department of Translational Tumor Immunology, Max-Delbrück-Center for Molecular Medicine, MDC, 13125, Berlin, Germany.
Trends Cancer. 2019 Jun;5(6):351-364. doi: 10.1016/j.trecan.2019.05.001. Epub 2019 Jun 5.
Despite progress in exploiting therapeutically the genetic vulnerabilities of leukemia and lymphoma, the outcome is often extended progression-free survival but not tumor eradication. Lymphomagenesis is not a tumor-autonomous process, and the onset and progression of tumors requires reciprocal crosstalk with the tumor microenvironment (TME). Minimal residual disease and immunosurveillance are also regulated by factors in the TME. Here, we dissect the stromal compartment in lymphoid organs, focusing on conditions that are prevalent in an autochthonous environment for lymphoid neoplasia. Identification of tumor-promoting factors is instrumental in the selection of therapeutic targets that are part of the immune system. Targeting the TME is an appealing treatment option for lymphoma because this compartment is subject to low selective pressure for mutations.
尽管在利用白血病和淋巴瘤的基因弱点进行治疗方面取得了进展，但结果往往是无进展生存期延长，而非肿瘤根除。淋巴瘤发生并非肿瘤自主过程，肿瘤的发生和进展需要与肿瘤微环境（TME）相互串扰。微小残留病和免疫监视也受TME中各种因素调节。在此，我们剖析淋巴器官中的基质区室，重点关注淋巴肿瘤原发环境中普遍存在的情况。鉴定肿瘤促进因子有助于选择作为免疫系统一部分的治疗靶点。针对TME是淋巴瘤一种有吸引力的治疗选择，因为该区域发生突变的选择压力较低。
